brain/
sourcestock-market

TMO Q2 2026 mix vs BIOSECURE / WuXi (Aug 2026)

TMO Q2 2026 pharma-services mix and last price; BIOSECURE/WuXi unnamed in the 10-Q; 1260H PI already in the vault.

Source

TMO Q2 2026 mix vs BIOSECURE / WuXi (Aug 2026)

Generated by Grok Bot research on 2026-08-27. WebSearch + fetch ladder + native X attempt. Treat as raw material — review before promoting into a project or thread. Attach to existing question biosecure-act-domestic-cdmo-reshoring. Context: vault/projects/stock-market.

Summary

Thermo Fisher's Q2 2026 10-Q (https://www.sec.gov/Archives/edgar/data/97745/000009774526000144/tmo-20260627.htm) prints pharma services (Patheon) at $1.893 billion, about 15.8% of $11.994 billion company sales, up 5.5% reported. BioProduction printed $941 million. Neither the 10-Q nor the 8-K Exhibit 99.1 release (https://www.sec.gov/Archives/edgar/data/97745/000009774526000138/q22026earnings8kex99_1.htm) names BIOSECURE or WuXi, so the July change condition is not met. The legal path versus that July prior does change: enacted Pub. L. 119-60 § 851 (https://www.congress.gov/119/plaws/publ60/PLAW-119publ60.htm, signed 18 Dec 2025) uses 1260H + OMB lists, not the 2024 named five (Baker McKenzie https://www.bakermckenzie.com/en/insight/publications/2026/01/united-states-the-biosecure-act-becomes-law). The 10 Jun 2026 Federal Register (https://www.govinfo.gov/content/pkg/FR-2026-06-10/pdf/2026-11571.pdf) added WuXi AppTec; WuXi Biologics is not in that notice. The 7 Aug 1260H preliminary injunction is already filed as 2026-08-26-autoresearch-biosecure-wuxi-1260h-injunction — do not re-assert as news. Last price: $630.70 at the Thursday 27 Aug 2026 4:00 PM EDT close (https://stockanalysis.com/stocks/tmo/). Keep TMO on the existing question. No DHR page. No new ticker. Gage empty.

Ingest rules (non-negotiable)

  1. Attach to EXISTING question vault/projects/stock-market/wiki/questions/biosecure-act-domestic-cdmo-reshoring.md. Do not invent that slug. Mechanism biosecure-cdmo-scarcity-to-western-cdmo-pricing-power.md already has the injunction — do not re-file 7 Aug as new.
  2. Update vault/projects/stock-market/wiki/entities/thermo-fisher.md: Q2 mix from the 10-Q (pharma services $1.893B / ~15.8% of $11.994B; BioProduction $941M tools; LSS organic 3%). Official 8-K Ex 99.1 for headline EPS/sales. Valuation mark: last price $630.70 as-of Thu 27 Aug 2026 4:00 PM EDT from stockanalysis. Empty Gage slot only. No invented target/downside/horizon.
  3. Correct the July prior on the question page: enacted statute is 1260H + OMB, not the 2024 named five. Cite Pub. L. 119-60 TOC + Baker McKenzie as law-firm recap (section body was truncated on congress.gov). FR 10 Jun added WuXi AppTec; WuXi Biologics not listed.
  4. Injunction: already in vault. Only new docket fact: DoD answer due 1 Sep 2026 (https://clearinghouse.net/case/48222/). Do not cite CourtListener PDFs or WuXi/HKEX PDFs (not retrieved this pass).
  5. Change condition NOT met. Do not graduate. Do not kill. KEEP-AS-QUESTION.
  6. Do NOT cite Motley Fool, JPM/wxerfm reprint, Pharma Manufacturing Investor Day, Vaxcyte MSA, or DynaDrive Hangzhou — those URLs were NOT fetched in this clip. Do not invent reshoring-win dollars.
  7. Casper “embedded in the outlook” is from an unfetched call transcript — do not file it.
  8. No DHR. No WuXi OTC entity (WUXAY/WUXIF quotes not fetched). No new product.
  9. Encyclopedia is not a source. Do not ingest encyclopedia.
  10. Native X was client-not-enrolled — no X citations.
  11. One PR. Do not merge.

Provenance

Method: Grok Bot / WebSearch + fetch ladder / native X attempt (client-not-enrolled) Generated: 2026-08-27

Web sources:

X sources:

  • none — native X was client-not-enrolled

Grokipedia:

  • not used
Referenced by
Questions
BIOSECURE Act + US biotech offshoring → domestic CDMO reshoring → XBI/CDMO beneficiary re-rate
Entities
Thermo Fisher Scientific (TMO)